A study of the clinical efficacy of frankincense in the acute phase of ischemic stroke

Document Type : Original Article


1 Neurology Dept., Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran

2 Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran

3 General Practitioner, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

4 Health Dept., Shahrekord University of Medical Sciences, Shahrekord, I.R. Iran

5 Mycology Dept., Shahid Sadoughi University of Medical Sciences of Yazd, Yazd, I.R. Iran


Background and aims: Ischemic stroke is the most common type of stroke and its most important symptoms are paralysis and movement disorders. Therefore, finding a method for treating this disorder is greatly important. This study was conducted to investigate the clinical efficacy of frankincense on the patients with ischemic stroke. Methods: In this clinical trial study, 60 patients with ischemic stroke were randomly assigned into two groups of treatment and control (30 patients in each group). In the treatment group, in addition to the routine treatment of stroke, four capsules containing 500 mg of powdered frankincense were used daily, but in the control group, only the treatment of stroke (without frankincense) was implemented. Treatment continued for one month. NIHSS questionnaire (to assess speech and muscle strength) was completed at the baseline, on the seventh day and at the end of treatment for each patient. In this study, statistical analysis was carried out by t- test, chi-square and Mann-Whitney using SPSS software. Results: The results showed that only in the second step in the treatment group, the rate of recovery of the left lower and muscle strength of upper limbs was significantly increased in patients compared to the control group. Conclusion: Introducing frankincense into treatment for stroke patients can contribute in improving muscle strength of the patients with muscle weakness in non-dominant hemisphere in acute phase of neurological disorder, while it has no effect improvement of muscle strength of right limbs or speech.


Main Subjects

1. Shiber JR, Fontane E, Adewale A. Stroke registry: hemorrhagic vs ischemic strokes. Am J Emerg Med. 2010; 28(3): 331-3.
2. Gillen G, Burkhardt A. stroke rehabilitation. 1st ed. New York: Mosby; 1998.
3. Herman B, Leyten AC, van Luijk JH, Frenken CW, Op de Coul AA, Schulte BP. Epidemiology of stroke in Tilburg, the Netherlands. The population-based stroke incidence register: 2. Incidence, initial clinical picture and medical care, and three-week case fatality. Stroke. 1982; 13(5): 629-34.
4. Hadjinikolaou L, Kotidis K, Galinanes M. Relationship between reduced elasticity of extracardiac vessels and left main stem coronary artery disease. Eur Heart J. 2004; 25(6): 508-13.
5. Nussmeier NA. A review of risk factors for adverse neurologic outcome after cardiac surgery. J Extra Corpor Technol. 2002; 34(1): 4-10.
6. Giele JL, Witkamp TD, Mali WP, van der Graaf Y, Group SS. Silent brain infarcts in patients with manifest vascular disease. Stroke. 2004; 35(3): 742-6.
7. Schellinger PD, Jansen O, Fiebach JB, Heiland S, Steiner T, Schwab S, et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke. 2000; 31(6): 1318-28.
8. Lauria G, Gentile M, Fassetta G, Casetta I, Agnoli F, Andreotta G, et al. Incidence and prognosis of stroke in the Belluno province, Italy. First-year results of a community-based study. Stroke. 1995; 26(10): 1787-93.
9. Ortiz GA, Koch S, Wallace DM, Lopez-Alberola R. Successful intravenous thrombolysis for acute stroke in a child. J Child Neurol. 2007; 22(6): 749-52.
10. Franceschini M, Carda S, Agosti M, Antenucci R, Malgrati D, Cisari C, et al. Walking after stroke: what does treadmill training with body weight support add to overground gait training in patients early after stroke?: a single-blind, randomized, controlled trial. Stroke. 2009; 40(9): 3079-85.
11. Archier P, Vieillescazes C. Characterization of various geographical origin incense based on chemical criteria. Analusis. 2000; 28(3): 233-7.
12. Thulin M, Warfa A. The frankincense trees (Boswellia spp., Burseraceae) of northern Somalia and southern Arabia. Kew Bulletin. 1987: 487-500.
13. Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006; 72(12): 1100-16.
14. Hamm S, Bleton J, Connan J, Tchapla A. A chemical investigation by headspace SPME and GC-MS of volatile and semi-volatile terpenes in various olibanum samples. Phytochemistry. 2005; 66(12): 1499-514.
15. Jauch J, Bergmann J. An Efficient Method for the Large‐Scale Preparation of 3‐O‐Acetyl‐11‐oxo‐β‐boswellic Acid and Other Boswellic Acids. Eur J Org Chem. 2003: 4752-6.
16. Rall B, Ammon HP, Safayhi H. Boswellic acids and protease activities. Phytomedicine. 1996; 3(1): 75-6.
17. Safayhi H, Mack T, Sabieraj J, Anazodo MI, Subramanian LR, Ammon HP. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992; 261(3): 1143-6.
18. Moussaieff A, Shein NA, Tsenter J, Grigoriadis S, Simeonidou C, Alexandrovich AG, et al. Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab. 2008; 28(7): 1341-52.
19. Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, et al. Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. Fed Am Soc Exp Biol. 2008; 22(8): 3024-34.
20. Hameed A. Avicenna's Tract on cardiac drugs and essays on Arab cardiotherapy. Pakistan: Hamdard Foundation Press; 1983.
21. Marshall S. Frankincense: festive pharmacognosy. Pharm J. 2003; 271: 862-4.
22. Hosseini Sharifabad M, Esfandiari E, Alaei H. Effects of frankincense aqueous extract during gestational period on increasing power of learning and memory in adult offsprings. J Isfahan Med Sch. 2004; 21(71): 16-20.
23. Hosseini M, Hadjzadeh MA, Derakhshan M, Havakhah S, Rassouli FB, Rakhshandeh H, et al. The beneficial effects of olibanum on memory deficit induced by hypothyroidism in adult rats tested in Morris water maze. Arch Pharm Res. 2010; 33(3): 463-8.
24. Sharma R, Singh S, Singh GD, Khajuria A, Sidiq T, Singh SK, et al. In vivo genotoxicity evaluation of a plant based antiarthritic and anticancer therapeutic agent Boswelic acids in rodents. Phytomedicine. 2009; 16(12): 1112-8.
25. Singh GB, Atal CK. Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent. Agents Actions. 1986; 18(3-4): 407-12.
26. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989; 20(7): 864-70.
27. Hosseini Sharifabad M, Esfandiary E. The Effects of Maternal Administration of Boswellia Gum Resin (Frankincense) during Lactation on Stereological Parameters of Rat Hippocampus. J Isfahan Med Sch. 2011; 29(165): 1-10.
28. Hosseini Sharifabad M, Esfandiari E. The Effects of Administration of Boswellia Gum (Boswellia serrata Triana & Planch) during Lactation on the morphology of neurons of Rat Hippocampus. J Herb Drug. 2011; 2(1): 45-52.
29. Cuaz-Perolin C, Billiet L, Bauge E, Copin C, Scott-Algara D, Genze F, et al. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2008; 28(2): 272-7.
30. Dashti GR, Esfandiari E, Nematbakhsh M, Saneei M, Jaafari Barmak M. a study of the effect of frankincense extract on the wall of coronary arteries(anterior and posterior interventricular branches) in high cholesterol fed male rabbits. J Isfahan Med Sch. 2005; 23(79): 63-8.
31. Kirste S, Treier M, Wehrle SJ, Becker G, Abdel-Tawab M, Gerbeth K, et al. Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. Cancer. 2011; 117(16): 3788-95.